文献速递眼底病与葡萄膜炎

呋喃硫胺通过抑制炎症与代谢重编程缓解脉络膜新生血管

Fursultiamine Alleviates Choroidal Neovascularization by Suppressing Inflammation and Metabolic Reprogramming.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

本研究在激光诱导的脉络膜新生血管(CNV)小鼠模型及RPE细胞中评估呋喃硫胺的疗效。结果显示呋喃硫胺显著减少血管渗漏和CNV病灶大小,降低炎症因子,增强线粒体呼吸,并减轻缺氧诱导的VEGF分泌与代谢异常,提示其可能成为新生血管性年龄相关性黄斑变性的候选疗法。

要点

  • 呋喃硫胺减少激光诱导CNV小鼠的血管渗漏和病灶大小。
  • 呋喃硫胺降低视网膜和脉络膜中IL-1β、IL-6、IL-8、TNF-α水平。
  • 呋喃硫胺增强RPE线粒体呼吸并抑制缺氧诱导的VEGF分泌。

核心结论

  • 呋喃硫胺可通过调节炎症反应和代谢重编程、增强RPE线粒体呼吸,成为新生血管性年龄相关性黄斑变性的潜在疗法。

研究设计与样本

  • 研究采用激光诱导的CNV小鼠模型,并在ARPE-19细胞和原代人RPE细胞中分别用LPS或缺氧处理进行体外验证。

主要发现

  • 在激光诱导CNV小鼠中,呋喃硫胺显著减少血管渗漏和病灶大小,并降低脉络膜和视网膜中IL-1β、IL-6、IL-8和TNF-α的数量。
  • 在LPS处理的ARPE-19细胞中,呋喃硫胺减少促炎细胞因子分泌和核因子κB磷酸化。
  • 在原代人RPE细胞中,呋喃硫胺以剂量和时间依赖方式抑制LPS诱导的IL-6、IL-8和单核细胞趋化蛋白-1上调。
  • 呋喃硫胺显著增强LPS处理的ARPE-19细胞的线粒体呼吸,并减轻缺氧诱导的乳酸生成和丙酮酸脱氢酶抑制性磷酸化。
  • 呋喃硫胺减轻缺氧诱导的原代人RPE细胞VEGF分泌和线粒体分裂,并在ARPE-19细胞中重现。

临床怎么用

  • 呋喃硫胺可能作为靶向RPE炎症与代谢重编程的候选药物,用于新生血管性年龄相关性黄斑变性的治疗探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the therapeutic effects of fursultiamine on choroidal neovascularization (CNV) through its modulation of inflammation and metabolic reprogramming in the retinal pigment epithelium (RPE). METHODS: The anti-angiogenic effects of fursultiamine were assessed by measuring vascular leakage and CNV lesion size in the laser-induced CNV mouse model. Inflammatory responses were evaluated by quantitative polymerase chain reaction, western blot, and ELISA in both CNV eye tissues and in vitro cell cultures using ARPE-19 cells or primary human RPE (hRPE) cells under lipopolysaccharide (LPS) treatment or hypoxia. Mitochondrial respiration was assessed by measuring oxygen consumption in ARPE-19 cells treated with LPS with or without fursultiamine, and lactate production was measured in ARPE-19 cells subjected to hypoxia with or without fursultiamine. RESULTS: In laser-induced CNV, fursultiamine significantly decreased vascular leakage and lesion size, as well as the numbers of both choroidal and retinal inflammatory cytokines, including IL-1β, IL-6, IL-8, and TNF-α. In LPS-treated ARPE-19 cells, fursultiamine decreased proinflammatory cytokine secretion and nuclear factor kappa B phosphorylation. Furthermore, fursultiamine suppressed LPS-induced upregulation of IL-6, IL-8, and monocyte chemoattractant protein-1 in a dose-dependent and time-dependent manner in primary hRPE cells. Interestingly, fursultiamine significantly enhanced mitochondrial respiration in the LPS-treated ARPE-19 cells. Additionally, fursultiamine attenuated hypoxia-induced aberrations, including lactate production and inhibitory phosphorylation of pyruvate dehydrogenase. Furthermore, fursultiamine attenuated hypoxia-induced VEGF secretion and mitochondrial fission in primary hRPE cells that were replicated in ARPE-19 cells. CONCLUSIONS: Our findings show that fursultiamine is a viable putative therapeutic for neovascular age-related macular degeneration by modulating the inflammatory response and metabolic reprogramming by enhancing mitochondrial respiration in the RPE.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Do JY, Kim J, Kim MJ, et al. Fursultiamine Alleviates Choroidal Neovascularization by Suppressing Inflammation and Metabolic Reprogramming. Invest Ophthalmol Vis Sci. 2020. PMID: 33107903. doi:10.1167/iovs.61.12.24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。